Wednesday, July 26, 2017 2:54:21 PM
http://www.dbmmgroup.com/dbmm-shareholders-update-back-basics-business-public-company/
1. The digital landscape is a growing aspect of the global economy and DBMM has proven its ability to be in the forefront.
2. “The 3Q 2015 revenues were up 39% to $368,364 for 9 months. Net loss was decreased 34% from $1,025,766 to $673,852. Expenses have decreased by 36% for the same period.”
3. The delayed filings will support the same trend as you will see once the reports are filed with the SEC via EDGAR.
4. Delayed audited 10-K and subsequent filings will document exactly what the Company has stated earlier.
5. DBMM’s agency has sought to optimize its reach by partnering with Google as a Premier Partner.
6. Regarding DBMM’s place in the sector, it is strong.
7. DBMM’s increasing client base and increasing revenues, coupled with decreasing debt and expenses, positions the Company as intended, thus attracting mezzanine financing.
8. DBMM has worked diligently to put toxic lending in the rear view mirror, engage mezzanine financing at “normal” market rates, to be repaid out of increased revenues, not equity.
9. DBMM continues the SEC process as stated in Release No. 4851/June 5, 2017. The Company has filed its Pre-Hearing Conference materials in considerable detail. It developed the Company’s earlier “Answer” in support of DBMM’s response as to why, for the first time, its filings were delayed.
10. DBMM is filing an 8-K as require to appoint the merged entity, Assurance Dimensions, as its Auditor-of-Record.
11. Also another Repeat-DBMM is owned by the shareholders. DBMM intends to resume trading. DBMM asks its shareholders for patience, for the time required to complete the SEC process. In the interim,
12. Updates will continue.
$DBMM
Recent DBMM News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/16/2024 09:32:32 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 11/29/2023 09:31:08 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/17/2023 09:15:45 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM